Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Registration - Inclusion Criteria
Age ≥18 years and be diagnosed with cancer and receiving chemotherapy
Ability to provide informed consent
Willingness to complete questionnaires
ECOG Performance Status (PS) 0, 1, 2
One or more of the following nasal symptoms for which the patient reports they would appreciate treatment. Symptoms must have started after the initiation of systemic, antineoplastic therapies, be attributed to the systemic, antineoplastic therapies, and symptoms must be reported as being moderate (corresponding to a score of 2) or worse on a scale from mild (1) to very severe (4) on at least one of the items below.
a. Dryness
b. Discomfort/Pain
c. Bleeding
d. Scabbing
e. Sores
Registration - Exclusion Criteria
Predisposition to epistaxis prior to the initiation of cancer-directed therapy (more than once a month over the previous year).
Planned initiation or continuation of any topical nasal treatment other than the studied nasal spray,( such as nasal steroids, Ayr nasal gel, Neosporin ointment or nasal administration of petroleum jelly). [SMY1] Taking Imitrex for migraines is acceptable.
Previous exposure to rose geranium in sesame oil nasal spray.
Concurrent upper respiratory tract infection
History of allergic or other adverse reactions to sesame oil or essential rose geranium oil
Any other reason that the study clinician or investigator feels precludes safe or appropriate inclusion in this study
Re-Registration:
The patient will be un-blinded and determined to have been on the saline arm, when initially randomized.